Established in 2008, Integral Biosciences Pvt. Ltd (IBS) is a drug discovery incubator, which offers end-to-end integrated drug discovery services to innovation focused biotech start-ups and small to mid-sized pharmaceutical companies. IBS is a well renowned Contract Research Organisation (CRO) in India providing preclinical development solution.
Works as an extension of partner’s scientific team
IBS works as an extension of their partner’s scientific think-tank rather than just a pure-play CRO and is open for collaborative projects for co-development of proprietary discovery portfolio with a flexible financial model. We have successful contract research partnerships with US based small to mid-size biotech companies for the development of oncology/CNS/metabolic disorders focused pipeline and our scientific contributions include the development of 2 drugs, 2 phase-I, 2 Phase-II and several pre-IND (Investigational New Drug) candidates in last 12 years.
IBS has a great success record for a company of 80-100 people, delivering from pre-clinical to clinical candidates. IBS can help with various aspects of early drug discovery including:-
- Starting new projects from scratch. We can help in market analysis, screening virtual libraries, designing molecules, etc.
- Advancing existing discovery projects.
- IP due diligence.
- Setting-up in-vivo studies. We have collaboration with CROs in India and outside India. We can help prospective clients in designing in-vivo experiments.
Our team have extensive experience in developing drug candidates against a broad range of target disease indications, which has provided us with one of the best track records in the industry.
Here, our primary asset is our knowledgeable & creative scientists. Our trained researchers draw upon years of experience in early stage drug discovery acquired across a wide range of therapeutic areas & biological targets. Through tractable hit-series identification & productive analogue design & syntheses, we can help you identify & optimise pre-clinical candidates in the area of small molecule drug discovery.
Focus On Early-Stage Hit-To-Lead
At IBS, we focus on early-stage hit-to-lead to determine promising lead compounds that can be successfully graduated to the optimization phase. Using technologies like high throughput screening, molecular modelling, structural biology, along with medicinal and computational chemistry helps in achieving our objective. This allows us to identify unique starting points for pre-clinical discovery processes with greater potential for success. The sooner a therapeutically advantageous lead compound is identified, the quicker the project can be taken to the next stage.
At Integral Biosciences, we believe in leveraging science for the benefit of humanity. It is our mission to develop better drugs for critical therapeutic areas including oncology, immuno-oncology and neurology. To achieve our objective, we have set up one of the most advanced drug discovery laboratories in India.
IBS is a modern drug discovery incubator that envisions a future where the treatments for critical illnesses become easily accessible to every affected human being. We are continuously enhancing our knowledge of different sciences and best practices so that we can discover and characterize newer and effective drug candidates against a broad range of target disease indications. At IBS, we want to make a difference in human lives by supporting innovative drug discovery and development.